Reputable news organizations such as Reuters, Agence France-Presse (AFP) and South African news website News24 debunked the ...

Several COVID-19 variants are acting uniquely enough to qualify as a distinct strain. And you might have heard about one on the news: the Delta variant. Today we’re going to talk about what it is, why ...

SHIMLA: After much delay, the Himachal Pradesh capital and Manali on Friday experienced the season's first snowfall, leading ...

JetZero says its $175 million Series B will be used to speed up development of its demonstrator ahead of anticipated first ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...

Pfizer's coronavirus-related sales have fallen sharply -- and they may decline even further next year. The company is developing some promising products, including a flu vaccine and a weight loss ...

The therapy YP05002 is part of the GLP-1 agonist class of drugs and is currently in early-stage development. Sign up here. Under the terms of the agreement, YaoPharma will complete the ongoing ...

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal. The U.S. drugmaker ...

Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...